Acceleron Pharma Receivables

Acceleron Pharma (XLRN) currently reports a receivables of $34M as of September 2021. That compares with $23M in the prior-year period — up 51.6% year over year. Use the charts on this page to explore Acceleron Pharma's receivables history and peer comparisons.

Acceleron Pharma's receivables increased from $23M to $34M — a 51.6% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acceleron Pharma reported $34M in receivables as of September 2021. That compares with $23M in the prior-year period — up 51.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $34M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acceleron Pharma, and consider following XLRN for alerts when major investors trade the stock.

Acceleron Pharma is classified in the Healthcare sector. On receivables, it currently shows $34M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLRN with unrelated industries.